AbbVie reports strong revenue growth amid market volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy ABBV?
Source: Fool
AbbVie Inc's stock fell 3.02% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 0.12% and the S&P 500 down 0.24%.
The company's revenue from its new drugs Skyrizi and Rinvoq surged to $5 billion and $2.37 billion in Q4 2025, reflecting year-over-year increases of 32% and 29.5%, respectively. This strong performance supports AbbVie's transition following the loss of Humira's exclusivity, enhancing its long-term profitability and stability as a Dividend King.
Despite the stock's decline, AbbVie's strong revenue growth indicates resilience in its business model, attracting investors seeking stability during market volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 208.990
Low
223.00
Averages
252.00
High
289.00
Current: 208.990
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Stocks to Hold for 20 Years
- AbbVie's Adaptability: AbbVie (ABBV) generated over $1 billion in sales from 12 drugs last year, and despite facing patent expirations and competitive pressures, the company successfully launched successors Rinvoq and Skyrizi, surpassing Humira's peak sales, demonstrating its strong market adaptability and future growth potential.
- Amazon's Ecosystem: Amazon (AMZN), the world's largest consumer discretionary company, dominates not only in e-commerce but also continuously expands in cloud computing and artificial intelligence, creating a sticky ecosystem that is difficult for competitors to disrupt, which is expected to continue attracting a large user base and drive long-term growth.
- Enbridge's Stability: Enbridge (ENB) operates the world's longest network of oil and liquid pipelines and is the largest natural gas utility in North America, with strong demand expected to persist over the next 20 years, particularly as natural gas and liquids usage rises, while its dividend growth provides stable returns for investors.
- Dividend Kings Potential: Both AbbVie and Enbridge have over 30 years of dividend growth records, with AbbVie already a Dividend King, and Enbridge expected to join this elite group in 19 years, showcasing their strong capabilities in shareholder returns and the attractiveness of long-term investments.
See More
Investment Opportunities in Psychedelic Therapy
- Massive Market Potential: With 100 million people globally suffering from treatment-resistant depression, representing one-third of all depression cases, psychedelic therapy presents significant growth opportunities, especially where traditional treatments fail.
- FDA Trial Progress: Compass Pathways' COMP 360 recently demonstrated a well-tolerated safety profile in Phase 3 trials, leading to a stock surge of over 23%, indicating a shift towards mainstream acceptance of psychedelics and the potential birth of a new healthcare category.
- Shift in Treatment Models: Unlike traditional daily medications, psychedelic therapy is an interventional approach requiring only 1-6 sessions for lasting effects, which could reshape investor perceptions of mental health treatments and attract more capital into the sector.
- Competitive Advantages in the Industry: As clinical applications of psychedelics increase, early market entrants like Compass Pathways will gain significant competitive advantages, prompting investors to monitor these companies' clinical advancements and market strategies.
See More
Investment Opportunities in Psychedelic Therapy
- FDA-Backed Shift: The transition of psychedelics from a counterculture fringe movement to an FDA-backed clinical model signifies a major transformation in mental health treatment, likely attracting investor interest in this emerging market.
- Huge Market Potential: Compass Pathways' COMP 360 demonstrated a well-tolerated safety profile in Phase 3 trials, with stock surging over 23%, indicating significant market potential for treating resistant depression affecting approximately 100 million patients globally.
- Innovative Treatment Model: Psychedelic therapy employs an interventional approach, differing from traditional medications, where patients typically require only 1 to 6 sessions, potentially offering investors new business models and revenue streams, especially in the $10,000 to $20,000 treatment services.
- Industry Competitive Landscape: While Big Pharma has not fully engaged yet, companies like AbbVie have begun acquiring smaller psychedelic firms, indicating growing interest in this emerging field, which could reshape the market dynamics of mental health treatment in the future.
See More
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
Analysis of AbbVie's Shareholding Changes
- Number of Holding Funds: As of March 31, 2026, 34 hedge funds held AbbVie (Ticker: ABBV), indicating ongoing market interest despite mixed positions among these funds.
- Position Changes: In this latest batch of 13F filings, 14 funds increased their ABBV holdings while 15 decreased them, suggesting divergent market views that could impact stock price volatility.
- Aggregate Holding Increase: Hedge funds' total ABBV holdings reached 13,835,675 shares as of March 31, 2026, up from 13,068,029 shares on December 31, 2025, reflecting an increase of 767,646 shares or approximately 5.87%, indicating overall bullish sentiment towards ABBV.
- Key Fund Movements: Capital Advisory Group Advisory Services LLC and Bright Futures Wealth Management LLC exited their ABBV positions during this period, signaling a shift in perspective among some funds that may affect investor confidence.
See More
Three High-Yield Stocks for Investors
- AbbVie's Stability: AbbVie saw a revenue increase of about 9% last year, primarily driven by strong performance in its immunology and neuroscience segments, making it a reliable investment during economic fluctuations, with a current dividend yield of 3.3%, significantly above the S&P 500's 1.2%.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it offers a dividend yield of 3.8%, showcasing its strong profitability in a high oil price environment, with operating profits exceeding $16 billion annually over the past four years.
- Vici Properties' Diversification: Vici Properties boasts a high dividend yield of 6.3%, with last year's revenue rising by 4% to over $4 billion and net income climbing to $2.8 billion, demonstrating its ability to withstand economic downturns, as evidenced by an almost 8% stock price increase in 2022.
- Investment Value Emergence: These three stocks have shown exceptional performance during market turbulence, with AbbVie and Chevron providing stable income and Vici Properties offering high dividends, making them top choices for investors, especially amid increasing economic uncertainty.
See More
Three Stocks to Hold for 20 Years
- AbbVie's Adaptability: AbbVie (ABBV) generated over $1 billion in sales from 12 drugs last year, and despite facing patent expirations and competitive pressures, the company successfully launched successors Rinvoq and Skyrizi, surpassing Humira's peak sales, demonstrating its strong market adaptability and future growth potential.
- Amazon's Ecosystem: Amazon (AMZN), the world's largest consumer discretionary company, dominates not only in e-commerce but also continuously expands in cloud computing and artificial intelligence, creating a sticky ecosystem that is difficult for competitors to disrupt, which is expected to continue attracting a large user base and drive long-term growth.
- Enbridge's Stability: Enbridge (ENB) operates the world's longest network of oil and liquid pipelines and is the largest natural gas utility in North America, with strong demand expected to persist over the next 20 years, particularly as natural gas and liquids usage rises, while its dividend growth provides stable returns for investors.
- Dividend Kings Potential: Both AbbVie and Enbridge have over 30 years of dividend growth records, with AbbVie already a Dividend King, and Enbridge expected to join this elite group in 19 years, showcasing their strong capabilities in shareholder returns and the attractiveness of long-term investments.
See More
Investment Opportunities in Psychedelic Therapy
- Massive Market Potential: With 100 million people globally suffering from treatment-resistant depression, representing one-third of all depression cases, psychedelic therapy presents significant growth opportunities, especially where traditional treatments fail.
- FDA Trial Progress: Compass Pathways' COMP 360 recently demonstrated a well-tolerated safety profile in Phase 3 trials, leading to a stock surge of over 23%, indicating a shift towards mainstream acceptance of psychedelics and the potential birth of a new healthcare category.
- Shift in Treatment Models: Unlike traditional daily medications, psychedelic therapy is an interventional approach requiring only 1-6 sessions for lasting effects, which could reshape investor perceptions of mental health treatments and attract more capital into the sector.
- Competitive Advantages in the Industry: As clinical applications of psychedelics increase, early market entrants like Compass Pathways will gain significant competitive advantages, prompting investors to monitor these companies' clinical advancements and market strategies.
See More
Investment Opportunities in Psychedelic Therapy
- FDA-Backed Shift: The transition of psychedelics from a counterculture fringe movement to an FDA-backed clinical model signifies a major transformation in mental health treatment, likely attracting investor interest in this emerging market.
- Huge Market Potential: Compass Pathways' COMP 360 demonstrated a well-tolerated safety profile in Phase 3 trials, with stock surging over 23%, indicating significant market potential for treating resistant depression affecting approximately 100 million patients globally.
- Innovative Treatment Model: Psychedelic therapy employs an interventional approach, differing from traditional medications, where patients typically require only 1 to 6 sessions, potentially offering investors new business models and revenue streams, especially in the $10,000 to $20,000 treatment services.
- Industry Competitive Landscape: While Big Pharma has not fully engaged yet, companies like AbbVie have begun acquiring smaller psychedelic firms, indicating growing interest in this emerging field, which could reshape the market dynamics of mental health treatment in the future.
See More
AbbVie's Stock Pullback Represents a Long-Term Buying Opportunity
- Reason for Stock Pullback: AbbVie's stock, which reached a record high of $238.71 on October 1, 2025, has pulled back about 13%, primarily due to overly optimistic market expectations for its new immunology drugs, Skyrizi and Rinvoq, leading investors to take profits amid increasing macroeconomic pressures.
- Market Performance Analysis: Over the past four years, AbbVie's stock has doubled, with a market cap of $369 billion and a current price of $209.03, indicating that despite short-term volatility, the company's fundamentals remain strong, complemented by a 4.02% dividend yield that attracts income-seeking investors.
- Future Growth Expectations: Analysts project AbbVie's EPS to increase more than fivefold from 2025 to 2028, driven by surging sales of new drugs, and while much of this growth is already priced in, the stock is still considered reasonably valued at 24 times this year's earnings.
- Investment Value Assessment: Despite the pressure from rising interest rates, AbbVie is viewed as a safe investment choice, particularly in a turbulent market, as its stable dividends and robust earnings growth prospects make it an ideal option for long-term investors.
See More
Analysis of AbbVie's Shareholding Changes
- Number of Holding Funds: As of March 31, 2026, 34 hedge funds held AbbVie (Ticker: ABBV), indicating ongoing market interest despite mixed positions among these funds.
- Position Changes: In this latest batch of 13F filings, 14 funds increased their ABBV holdings while 15 decreased them, suggesting divergent market views that could impact stock price volatility.
- Aggregate Holding Increase: Hedge funds' total ABBV holdings reached 13,835,675 shares as of March 31, 2026, up from 13,068,029 shares on December 31, 2025, reflecting an increase of 767,646 shares or approximately 5.87%, indicating overall bullish sentiment towards ABBV.
- Key Fund Movements: Capital Advisory Group Advisory Services LLC and Bright Futures Wealth Management LLC exited their ABBV positions during this period, signaling a shift in perspective among some funds that may affect investor confidence.
See More
Three High-Yield Stocks for Investors
- AbbVie's Stability: AbbVie saw a revenue increase of about 9% last year, primarily driven by strong performance in its immunology and neuroscience segments, making it a reliable investment during economic fluctuations, with a current dividend yield of 3.3%, significantly above the S&P 500's 1.2%.
- Chevron's Resilience: During the market crash in 2022, Chevron's stock surged by 53%, and it offers a dividend yield of 3.8%, showcasing its strong profitability in a high oil price environment, with operating profits exceeding $16 billion annually over the past four years.
- Vici Properties' Diversification: Vici Properties boasts a high dividend yield of 6.3%, with last year's revenue rising by 4% to over $4 billion and net income climbing to $2.8 billion, demonstrating its ability to withstand economic downturns, as evidenced by an almost 8% stock price increase in 2022.
- Investment Value Emergence: These three stocks have shown exceptional performance during market turbulence, with AbbVie and Chevron providing stable income and Vici Properties offering high dividends, making them top choices for investors, especially amid increasing economic uncertainty.
See More
